Supplementary Material

# A familial novel putative-pathogenically mutation identified in plaque-psoriasis by a multigene panel analysis

Marcella Nunziato[1,2†], Anna Balato[3], Anna Ruocco[1,2†], Valeria D'Argenio[1,2,4], Roberta Di Caprio[5], Nicola Balato[6], Fabio Ayala[7] and Francesco Salvatore[1,2*]

[1]CEINGE-Biotecnologie Avanzate Franco Salvatore, via Gaetano Salvatore 486, 80145 Naples, Italy
[2]Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, via Sergio Pansini 5, 80131 Naples, Italy
[3]Dermatology Unit, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy
[4]Department of Human Sciences and Quality of Life Promotion, San Raffaele Open University, 00166 Roma, Italy.
[5]Microbiology and Virology unit, Cotugno Hospital, AORN dei Colli, Via Gaetano Quagliariello, 54, 80131, Naples, Italy
[6] Italian "School of Psoriasis" Association, 81031 Aversa, Italy
[7]Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy via Sergio Pansini 5, 80131 Naples, Italy

[†]These authors contributed equally to this work.
[*]Corresponding Author

**Supplementary Table S1**. List of the genes included in our custom multigene panel, and their chromosomal localization.

| N° | Name | Chromosome | N° | Name | Chromosome | N° | Name | Chromosome | N° | Name | Chromosome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | *ACE* | chr17 | 25 | *HLA-C* | chr6 | 49 | *IVL* | chr1 | 73 | *RNF114* | chr20 |
| 2 | *ADAM33* | chr20 | 26 | *HLA-DQA1* | chr6 | 50 | *KIR2DS1* | chr19 | 74 | *S100A12* | chr1 |
| 3 | *ADRB2* | chr5 | 27 | *HLA-DQB1* | chr6 | 51 | *LCE3B* | chr1 | 75 | *S100A7* | chr1 |
| 4 | *AGER* | chr6 | 28 | *HLA-DRB1* | chr6 | 52 | *LCE3C* | chr1 | 76 | *S100A8* | chr1 |
| 5 | *APOE* | chr19 | 29 | *HTR2A* | chr13 | 53 | *MGST2* | chr4 | 77 | *S100A9* | chr1 |
| 6 | *CARD14* | chr17 | 30 | *IFIH1* | chr2 | 54 | *MICA* | chr6 | 78 | *SLC12A8* | chr3 |
| 7 | *CCHCR1* | chr6 | 31 | *IFNG* | chr12 | 55 | *MIF* | chr22 | 79 | *SLC6A4* | chr17 |
| 8 | *CCL2* | chr17 | 32 | *IL10* | chr1 | 56 | *MMP2* | chr16 | 80 | *SLC9A3R1* | chr17 |
| 9 | *CD226* | chr18 | 33 | *IL12B* | chr5 | 57 | *MTHFR* | chr1 | 81 | *SPRR1A* | chr1 |
| 10 | *CDKAL1* | chr6 | 34 | *IL13* | chr5 | 58 | *NAT2* | chr8 | 82 | *SPRR1B* | chr1 |
| 11 | *CDSN* | chr6 | 35 | *IL15* | chr4 | 59 | *NAT9* | chr17 | 83 | *SPRR2A* | chr1 |
| 12 | *CSTA* | chr3 | 36 | *IL18* | chr11 | 60 | *NFKB1* | chr4 | 84 | *STAT4* | chr2 |
| 13 | *CX3CR1* | chr3 | 37 | *IL19* | chr1 | 61 | *NFKBIA* | chr14 | 85 | *TAP1* | chr6 |
| 14 | *DEFB103A* | chr8 | 38 | *IL1B* | chr2 | 62 | *NOS3* | chr7 | 86 | *TCF19* | chr20 |
| 15 | *DEFB103B* | chr8 | 39 | *IL2* | chr4 | 63 | *PGLYRP3* | chr1 | 87 | *TAP2* | chr6 |
| 16 | *DEFB104A* | chr8 | 40 | *IL20* | chr1 | 64 | *PGLYRP4* | chr1 | 88 | *TNF* | chr6 |
| 17 | *DEFB104B* | chr8 | 41 | *IL20RA* | chr6 | 65 | *POU5F1* | chr6 | 89 | *TNFAIP3* | chr6 |
| 18 | *DEFB4A* | chr8 | 42 | *IL23A* | chr12 | 66 | *PRINS* | chr10 | 90 | *TNIP1* | chr5 |
| 19 | *DEFB4B* | chr8 | 43 | *IL23R* | chr1 | 67 | *PRR9* | chr1 | 91 | *TRAF3IP2* | chr6 |
| 20 | *ERAP1* | chr5 | 44 | *IL28RA* | chr1 | 68 | *PSORS1C1* | chr6 | 92 | *TYK2* | chr19 |
| 21 | *FLG* | chr1 | 45 | *IL4* | chr5 | 69 | *PSORS1C2* | chr6 | 93 | *VDR* | chr12 |
| 22 | *FLT4* | chr5 | 46 | *IL4R* | chr16 | 70 | *PSORS1C3* | chr6 | 94 | *VEGFA* | chr6 |
| 23 | *FOXP3* | chrX | 47 | *IL6* | chr7 | 71 | *PTPN22* | chr1 | 95 | *ZAP70* | chr2 |
| 24 | *HLA-B* | chr6 | 48 | *IRF2* | chr4 | 72 | *REL* | chr2 | 96 | *ZNF750* | chr17 |




**Supplementary Figure S1**. The experimental protocol used in this study.